Imu asx

Financial Times Close.

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus.

Imu asx

January 19, Bronwyn Allen. Investors are excited over some further news released by the company today. January 17, James Mickleboro. November 28, James Mickleboro. November 10, James Mickleboro. The healthcare stock is roaring higher again on Friday. But what's getting investors excited? November 9, James Mickleboro. November 8, James Mickleboro. November 6, James Mickleboro. November 6, Bernd Struben. September 25, James Mickleboro.

Forecast to breakeven in Jun

Bringing effective new treatments and options to patients who need them. PD1-Vaxx is a B-cell immuno-therapy which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies. Sign up with your email address to receive news and updates. Mission and Values. Leadership Team. Management Team.

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd. IMM 8. Pilbara Minerals Ltd. PLS 0.

Imu asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders.

Crystal bernard naked

Thank you for registering. Earnings are forecast to grow Mission and Values. He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. Cogstate Ltd. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. Add to Your Watchlists New watchlist. Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. Apr How do Imugene's earnings and revenue compare to its market cap? Participants resources. Price target decreased by 9.

Financial Times Close.

January 19, Bronwyn Allen. Click or tap a row for details. Price Volatility. About the company Imugene Limited is a clinical-stage immune-oncology company. CF33 Oncolytic Virus. A verification email has been sent. Last Name. Any information that you receive via FT. Last Reported Earnings Dec 31, Trade our cash market. Actions Add to watchlist Add to portfolio Add an alert.